×
Published on 1 March 2021

Roche integrates the Accu-Chek Insight insulin pump into the automated insulin delivery (AID) system from Diabeloop

  • The Accu-Chek Insight insulin pump from Roche will be the first pump with a pre-filled cartridge that can be operated in loop mode.
  • As part of DBLG1 System from Diabeloop, the Accu-Chek Insight insulin pump will enable people with diabetes to better manage their diabetes and improve their time in range.
Basel, 01 March 2021 - Roche today announced that the Accu-Chek Insight insulin pump will support automated insulin delivery (AID) by partnering with Diabeloop, a French MedTech company pioneering therapeutic artificial intelligence. People with diabetes will have the option to use an insulin pump in a hybrid closed-loop system which features a pre-filled cartridge of insulin and the possibility to set up very low basal rates to suit individual needs. By advancing its insulin pump technology, Roche embraces its vision to bring innovation to people with diabetes allowing them to worry less about their treatment and helping them to experience true relief.
 
The Accu-Chek Insight insulin pump will be part of DBLG1 System from Diabeloop. Within this CE-labelled system, it will be connected to a continuous glucose monitoring system and DBLG1 – Diabeloop’s self-learning algorithm hosted in a dedicated handset. This algorithm analyses data in real time and decides whether to stop insulin delivery, adjust basal rate delivery, or even deliver an automatic correction bolus when needed.1
 
“Diabetes management is complex and personal, and achieving therapy goals is an ongoing challenge. The integration of the Accu-Chek Insight insulin pump into an AID system creates new opportunities to lower the burden of constant insulin dose adjustment for people with diabetes,” said Marcel Gmuender, Head of Roche Diabetes Care. “By partnering with Diabeloop, we’ll help people with diabetes get more out of life by supporting them to automatically meet their personal insulin needs day and night. At Roche, we believe that the more personalised therapy is, the better the outcomes will be.“
 
With its sleek design, intuitive user guidance and pre-filled cartridge the Accu-Chek Insight insulin pump has been a companion for people with diabetes since 2014. In early 2021, people with diabetes in Germany, Italy, Spain, Switzerland, and the Netherlands will be able to operate the Accu-Chek Insight insulin pump in hybrid-closed loop mode. The roll-out in first countries across Europe marks Roche’s first step in the field of automated insulin delivery representing a milestone in its strategy of integrated Personalised Diabetes Management (iPDM).
 
“Together with Roche, we are aiming to give people with diabetes a new opportunity in their insulin pump therapy,” stated Marc Julien, co-CEO of Diabeloop. “The integration of the Accu-Chek Insight insulin pump into our DBLG1 System will allow Diabeloop to propose our safe and personalised solution of automated diabetes management to more people with diabetes across Europe.” 
 
About hybrid closed-loop systems
Hybrid closed-loop systems are made up of a continuous glucose monitor, an insulin pump, and an algorithm which analyses glucose measurements in real-time. Every few minutes, a glucose value is transmitted to the device hosting the algorithm which calculates and adjusts the insulin delivery automatically. The needed doses of insulin are determined taking into account people’s physiology, total daily dose of insulin, and meal information. The systems are considered "hybrid" because users need to announce meal intakes and command the bolus doses to cover the meals. The system continually automates basal insulin delivery to maintain glucose levels in the target range. Some systems are also able to automatically deliver correction boluses as they are needed to bring glucose values back to the target range.
 
References
[1] Benhamou PY, Franc S, Reznik Y, et al. Closed-loop insulin delivery in adults with type 1 diabetes in real-life conditions: a 12-week multicentre, open-label randomised controlled crossover trial. Lancet Digital Health. 2019;1: e17–25.
 
For more information contact: [email protected]
- Soo-Jin Pak
- Yvette Petillon